Avrobio News

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients With Preserved Ejection Fraction Heart Failure

Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on

BusinesswireMar 26 19:06

AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders

TipRanksMar 16 14:01

Avrobio (AVRO) Gets a Buy From Wells Fargo

TipRanksMar 15 18:47

Shareholder Alert: Ademi LLP Investigates Whether AVROBIO, Inc. Has Obtained a Fair Price in Its Transaction With Tectonic

MILWAUKEE, Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic.

PR NewswireFeb 1 04:08

Avrobio Buy Rating: Undervalued Merger Potential With Tectonic and Promising Fc-relaxin Asset for G2PH

TipRanksJan 31 18:50

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVROBIO, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - January 30, 2024) - Rigrodsky Law, P.A. is investigating AVROBIO, Inc. ("AVROBIO") (NASDAQ GS: AVRO) regarding possible breaches of fiduciary duties and other v

newsfileJan 31 05:21

Avrobio Shares Dive 17% After Tectonic Therapeutic Deal

Avrobio shares dived 17% to $1.14 after it agreed to merge with Tectonic Therapeutic in an all-stock deal that will see Tectonic take Avrobio's place on the public markets.

WSJJan 30 23:28

Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt Status Updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaJan 30 21:25

AVROBIO And Tectonic Therapeutic Announce Merger In All-Stock Transaction; AVROBIO To Acquire 100% Of Outstanding Equity Interests Of Tectonic

AVROBIO And Tectonic Therapeutic Announce Merger In All-Stock Transaction; AVROBIO To Acquire 100% Of Outstanding Equity Interests Of Tectonic

BenzingaJan 30 21:04

AVROBIO: Upon Completion of Merger, Combined Co Expected to Operate Under the Name Tectonic Therapeutic and Trade on Nasdaq Under Ticker Symbol TECX >AVRO

AVROBIO: Upon Completion of Merger, Combined Co Expected to Operate Under the Name Tectonic Therapeutic and Trade on Nasdaq Under Ticker Symbol TECX >AVRO

Dow JonesJan 30 21:03

AVROBIO: Tectonic Has Raised or Entered Into Agreements for a $130.7M Private Placement With a Syndicate of New and Existing Leading Life Sciences Investors >AVRO

AVROBIO: Tectonic Has Raised or Entered Into Agreements for a $130.7M Private Placement With a Syndicate of New and Existing Leading Life Sciences Investors >AVRO

Dow JonesJan 30 21:03

AVROBIO: Combined Co to Be Nasdaq-listed, Clinical-Stage Biopharmaceutical Co Focused on Advancing Tectonic's Novel GPCR-targeted Therapeutic Proteins >AVRO

AVROBIO: Combined Co to Be Nasdaq-listed, Clinical-Stage Biopharmaceutical Co Focused on Advancing Tectonic's Novel GPCR-targeted Therapeutic Proteins >AVRO

Dow JonesJan 30 21:02

AVROBIO: Combined Co Expected to Have Approximately $165 M in Cash and Cash Equivalents at Close to Provide Cash Runway Into Mid-2027 >AVRO

AVROBIO: Combined Co Expected to Have Approximately $165 M in Cash and Cash Equivalents at Close to Provide Cash Runway Into Mid-2027 >AVRO

Dow JonesJan 30 21:02

AVROBIO: Will Acquire 100% of the Outstanding Equity Interests of Tectonic >AVRO

AVROBIO: Will Acquire 100% of the Outstanding Equity Interests of Tectonic >AVRO

Dow JonesJan 30 21:02

AVROBIO and Tectonic Therapeutic Announce Merger

AVROBIO and Tectonic Therapeutic Announce Merger

Dow JonesJan 30 21:01

Trading Halt: Halted at 7:55:00 A.m. ET - Trading Halt: Halt News Pending

Trading Halt: Halted at 7:55:00 A.m. ET - Trading Halt: Halt News Pending

BenzingaJan 30 20:55

AVROBIO Cut to Neutral From Buy by Mizuho

AVROBIO Cut to Neutral From Buy by Mizuho

Dow JonesDec 19, 2023 00:45

AVROBIO Price Target Cut to $2.00/Share From $5.00 by Mizuho

AVROBIO Price Target Cut to $2.00/Share From $5.00 by Mizuho

Dow JonesDec 19, 2023 00:45

Mizuho Downgrades Avrobio to Neutral, Lowers Price Target to $2

Mizuho analyst Uy Ear downgrades Avrobio (NASDAQ:AVRO) from Buy to Neutral and lowers the price target from $5 to $2.

BenzingaDec 19, 2023 00:36

Potential Growth and Strategic Alternatives: Reasons Behind Zhu's Buy Rating for Avrobio

TipRanksNov 13, 2023 18:39